Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.67 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.67 |
| ▸ | FPR2 | P25090 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | FPR1 | P21462 | 1/20 | 0.65 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | ALPL | P05186 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406237 | 1.00 | NPC1 (0.69) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4674353 | 0.88 | NPC1 (0.67) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5391948 | 0.86 | CYP1A2 (0.76) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27203365 | 0.81 | NPC1 (0.67) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL944312 | 0.81 | POLB (0.72) | NPC1RAB9AMAPTALDH1A1POLB | |
| SCHEMBL4674103 | 0.79 | NPC1 (0.55) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4675296 | 0.78 | NPC1 (0.53) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4675291 | 0.78 | NPC1 (0.53) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5391945 | 0.77 | CYP1A2 (0.63) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9743301 | 0.77 | CYP2E1 (0.76) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2555768-A2 | IRE-1 INHIBITORS | MannKind Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011127070-A2 | IRE-1α INHIBITORS | MANNKIND CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | NPC1 822/4885RAB9A 1146/4885CYP1A2 2785/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | NPC1 628/4885RAB9A 1149/4885CYP1A2 2509/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | NPC1 822/4885RAB9A 1146/4885CYP1A2 2785/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | NPC1 628/4885RAB9A 1149/4885CYP1A2 2509/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | NPC1 705/4885RAB9A 1093/4885CYP1A2 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.